Prognostic importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review
محل انتشار: هفدهمین همایش سالانه آسیب شناسی و طب آزمایشگاه
سال انتشار: 1394
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 436
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ACPLMED17_016
تاریخ نمایه سازی: 20 آبان 1397
چکیده مقاله:
Background: Acute myeloid leukemia (AML) is defined as the reproduction of leukemic blasts in the bone marrow, which could develop as the primary or secondary type. Chromosomal abnormalities could form different subgroups with joint clinical specifications and results, which are described as core binding factor acute myeloid leukemia (CBF-AML), including t(8;21)(q22;q22) and inv(16)(p13;q22), in the core binding factor. Activating c-kit gene mutations account for 12.8% and 46.1% of the adults presented with core binding factor leukemia (CBFL), and these mutations are known to occur in 20-25% of the cases with t(8;21) and 30% of the cases with inv(16). Materials and Methods: In this systematic review, we searched different databases, including PubMed, Scopus, Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts.Finally, articles relevant to the subject of this review were retrieved in full text. 22 articles matched for inclusion criteria and selected for this review.Results: In this study, c-kit mutations were observed to have poor prognostic significance in AML patients with t(8;21) and inv(16). In addition, these mutations had a better prognostic effect on AML patients with inv(16) compared to those with t(8;21). Conclusion: According to the results of this study, c-kit mutations had intense, harmful effects on the relapse and high white blood cell count of the adult patients with CBF-AML. However, these mutations had no prognostic significance in the survival of these patients
نویسندگان
hossein ayatollahi
MD, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Maryam Sheikhi
Msc. Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
arezoo Shajiee
MD, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad Hadi Sadeghian
MD, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran